Literature DB >> 26819183

A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy.

Raymond C Rosen1, Allen D Seftel2, Dustin D Ruff3, David Muram3.   

Abstract

Men with hypogonadism (HG) who choose testosterone replacement therapy (TRT) may have distinct characteristics that provide insight as to why they may/may not initiate therapy. The aim of the current study was to identify trends in patient characteristics and attitudes in men diagnosed with HG who initiated TRT (TRT+) compared with men who were diagnosed with HG but did not initiate TRT (TRT-). The market research-based online survey conducted between 2012 and 2013 included patients from a Federated Sample, a commercially available panel of patients with diverse medical conditions. The current analysis was composed of two groups: TRT+ ( n = 155) and TRT- ( n = 157). Patient demographics, clinical characteristics, and attitudes toward HG and TRT were examined as potential predictors of primary adherence in men with HG; cohorts were compared by using Fisher's exact test. Significant associations among sexual orientation, relationship status, educational level, presence of comorbid erectile dysfunction, area of residence, and TRT initiation were present ( p ≤ .05). College-educated, heterosexual, married men with comorbid erectile dysfunction living in suburban and urban areas were more likely to initiate treatment. The most bothersome symptoms reported were lack of energy (90% vs. 81%, p = .075), decreased strength and endurance (86% vs. 76%, p = .077), and deterioration in work performance (52% vs. 31%, p = .004); lack of energy prompted men to seek help. Patients (48%) in the TRT+ group were more knowledgeable regarding HG as compared with TRT- respondents (14%, p < .001), and most men obtained their information from a health care professional (89% vs. 82%, p = .074). The current analysis identified distinct demographic and clinical characteristics and attitudes among TRT users compared with men who were diagnosed with HG yet remained untreated.

Entities:  

Keywords:  hypogonadism; market research survey; patient characteristics; testosterone replacement therapy

Mesh:

Substances:

Year:  2016        PMID: 26819183      PMCID: PMC5987957          DOI: 10.1177/1557988315625773

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  27 in total

1.  Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions.

Authors:  Emmanuele A Jannini; Andrea M Isidori; Antonio Aversa; Andrea Lenzi; Stanley E Althof
Journal:  J Sex Med       Date:  2013-10       Impact factor: 3.802

2.  Prevalence of sexual problems and related help-seeking behaviors among mature adults in Brazil: data from the global study of sexual attitudes and behaviors.

Authors:  Edson Duarte Moreira Junior; Dale Glasser; Djanilson Barbosa dos Santos; Clive Gingell
Journal:  Sao Paulo Med J       Date:  2005-12-08       Impact factor: 1.044

3.  Primary medication non-adherence: analysis of 195,930 electronic prescriptions.

Authors:  Michael A Fischer; Margaret R Stedman; Joyce Lii; Christine Vogeli; William H Shrank; M Alan Brookhart; Joel S Weissman
Journal:  J Gen Intern Med       Date:  2010-02-04       Impact factor: 5.128

Review 4.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

Review 5.  Risks and benefits of testosterone therapy in older men.

Authors:  Matthew Spitzer; Grace Huang; Shehzad Basaria; Thomas G Travison; Shalender Bhasin
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

6.  Factors associated with first-fill adherence rates for diabetic medications: a cohort study.

Authors:  Nirav R Shah; Annemarie G Hirsch; Christopher Zacker; Scott Taylor; G Craig Wood; Walter F Stewart
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

7.  Trends in androgen prescribing in the United States, 2001 to 2011.

Authors:  Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

8.  Prevalence of symptomatic androgen deficiency in men.

Authors:  Andre B Araujo; Gretchen R Esche; Varant Kupelian; Amy B O'Donnell; Thomas G Travison; Rachel E Williams; Richard V Clark; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2007-08-14       Impact factor: 5.958

9.  Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.

Authors:  Michael Jay Schoenfeld; Emily Shortridge; Zhanglin Cui; David Muram
Journal:  J Sex Med       Date:  2013-03-06       Impact factor: 3.802

10.  Factors affecting therapeutic compliance: A review from the patient's perspective.

Authors:  Jing Jin; Grant Edward Sklar; Vernon Min Sen Oh; Shu Chuen Li
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more
  2 in total

Review 1.  The Role of the "Anti-Inflammatory" Couple for the Management of Hyperuricemia With Deposition.

Authors:  Andrea Sansone; Yacov Reisman; Suada Meto; Susanna Dolci; Emmanuele A Jannini
Journal:  Sex Med       Date:  2022-09-07       Impact factor: 2.523

2.  Sex, Energy, Well-Being and Low Testosterone: An Exploratory Survey of U.S. Men's Experiences on Prescription Testosterone.

Authors:  Alex A Straftis; Peter B Gray
Journal:  Int J Environ Res Public Health       Date:  2019-09-05       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.